Actively Recruiting
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Led by Alnylam Pharmaceuticals · Updated on 2026-05-14
144
Participants Needed
22
Research Sites
130 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this study is to: * evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 * evaluate the efficacy, safety, tolerability, and pharmacodynamics (PD) of multiple doses of ALN-4324 in adult overweight to obese patients with T2DM
CONDITIONS
Official Title
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
Who Can Participate
Eligibility Criteria
You may qualify if you...
- For Part A: Body mass index (BMI) of at least 27 kg/m² and less than 40 kg/m²
- For Part B: Adult patients with confirmed type 2 diabetes mellitus (T2DM)
- For Part B: Hemoglobin A1c (HbA1c) between 7% and less than 10.5%
- For Part B: BMI of at least 25 kg/m² and less than 45 kg/m²
- For Part B: Stable dose of metformin alone or metformin with a sodium-glucose cotransporter 2 inhibitor (SGLT2i)
You will not qualify if you...
- For Part A: Known HIV infection or current/chronic hepatitis B or C infection
- For Part B: Use of chronic weight management therapies or antidiabetic medications other than metformin and SGLT2i
- Other protocol-defined inclusion and exclusion criteria may apply
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 22 locations
1
Clinical Trial Site
Montclair, California, United States, 91763
Actively Recruiting
2
Clinical Trial Site
Washington D.C., District of Columbia, United States, 20009
Not Yet Recruiting
3
Clinical Trial Site
Miami, Florida, United States, 33126
Actively Recruiting
4
Clinical Trial Site
Marlton, New Jersey, United States, 08053
Actively Recruiting
5
Clinical Trial Site
Monroe, North Carolina, United States, 28112
Actively Recruiting
6
Clinical Trial Site
Dallas, Texas, United States, 75230
Actively Recruiting
7
Clinical Trial Site
Dallas, Texas, United States, 75246
Actively Recruiting
8
Clinical Trial Site
Buenos Aires, Argentina, C1060
Actively Recruiting
9
Clinical Trial Site
Buenos Aires, Argentina, C1061AAE
Actively Recruiting
10
Clinical Trial Site
Buenos Aires, Argentina, C1061
Actively Recruiting
11
Clinical Trial Site
San Miguel de Tucumán, Argentina, T4000IHE
Actively Recruiting
12
Clinical Trial Site
Concord, Canada, L4K 4M2
Actively Recruiting
13
Clinical Trial Site
Mount Royal, Canada, H3P 3P1
Actively Recruiting
14
Clinical Trial Site
Vancouver, Canada, V5Y 3W2
Not Yet Recruiting
15
Clinical Trial Site
Santiago, Chile, 7500710
Not Yet Recruiting
16
Clinical Trial Site
Santiago, Chile, 7770086
Not Yet Recruiting
17
Clinical Trial Site
Santiago, Chile, 8320000
Actively Recruiting
18
Clinical Trial Site
Essen, Germany, 45355
Actively Recruiting
19
Clinical Trial Site
Gdansk, Poland, 80-546
Actively Recruiting
20
Clinical Trial Site
Tarnów, Poland, 33-100
Not Yet Recruiting
21
Clinical Trial Site
Warsaw, Poland, 02-507
Actively Recruiting
22
Clinical Trial Site
Wroclaw, Poland, 51-162
Actively Recruiting
Research Team
A
Alnylam Clinical Trial Information Line
CONTACT
A
Alnylam Clinical Trial Information Line
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
TRIPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here